📌Reminder: start following us on Blue Sky! https://t.co/2a6Kmv5JtL We'll be migrating there after #INTEREST2025.

Get to know the early-career African researchers who submitted the highest-scoring scientific abstracts to this year's INTEREST conference Patane Shilabye & Clark Brianwong explain why they study what they do + what’s next for them: https://t.co/SSKglRF3JO

#ThrowbackThursday Did you catch any of our presentations at @INTERESTconf 2025? If not, no worries! Explore all the impactful posters from the Pangaea Zimbabwe team here: https://t.co/XFHqkE7qkY Want them straight to your inbox? Sign up here: https://t.co/ggubKjV2nc

⁦@INTERESTconf⁩ 2025 was more exciting than ever. Always Looking forward to next!

🎉Patane Shilabye (#SouthAfrica) & Clark Joshua Brianwong (#Uganda)🎉are the winners of the Joep Lange & Charles Boucher Awards for the highest-scoring abstracts by early-career African scientists! Selected from more than 1,700 abstracts, Patane and Clark presented their

Conference Closure #INTEREST2025 absolutely amazing

Art and Health #INTEREST2025

2️⃣Factors Associated with Recent Physical Violence among Orphaned and Vulnerable Children (OVC) in #Namibia Adolescents aged 15–19 years were at higher risk of experiencing violence compared to younger children aged 10–14. Children with disabilities reported lower levels of

The results identify five major themes that prevent adolescents & young people (AYP) from accessing sexual and reproductive health (SRH) and HIV services: 1️⃣Socio-cultural and religious influences – This includes healthcare worker stigma, myths and misconceptions about SRH, and

Mini-Oral Abstract Presentations VI, chaired by Dr Wendy Spearman (@UCT_news) & Ndeshi Nashandi 1️⃣Using Photovoice as a Community-Based Participatory Research Tool to Inform Intervention Development for Young People’s Improved Access to Sexual and Reproductive Health Services in

We are at #INTEREST2025, Africa’s premier HIV science conference taking place from 13–16 May in Windhoek, Namibia. Our staff, Clark Joshua Brianwong, shared about how we are leveraging electronic case-based surveillance system (eCBSS) data for geospatial mapping of TB hotspots

@DTHF_SA @UCT_news @FrancoisVenter3 Take-home messages: 1️⃣CAB (cabotegravir) shows strong efficacy, but virological failure often results in cross-resistance to other integrase inhibitors (INI). 2️⃣Low drug levels are frequently observed at virological failure, although they are not an independent predictor. 3️⃣Viral

@DTHF_SA @UCT_news @FrancoisVenter3 Data from the ATHENA cohort, which included 585 individuals on injectable therapy, showed a high virologic failure rate of 9%. Notably, more than 105 people initiated on cabotegravir/rilpivirine (CAB/RPV) did not meet eligibility criteria due to prior drug resistance or previous

@DTHF_SA @UCT_news @FrancoisVenter3 CAB failure rate in clinical trials is extremely low: 1.6 – 2.1% Lower incidence with CAB-LA, but the proportion of breakthrough infections that are resistant is higher in men/trans women ~ Dr Annemarie Wensing

@DTHF_SA @UCT_news @FrancoisVenter3 "There's tons of work ahead, particularly when our biggest donor suddenly pulled the rug from underneath us. It's an exciting time, but it's a very complicated time – and it's going to be a tragic time if we don't take the new innovations and technologies into the rightful place,

@DTHF_SA @UCT_news @FrancoisVenter3 Other innovations in development include over 17 monoclonal antibodies currently under evaluation, long-acting tenofovir alafenamide (TAF), and subcutaneous formulations of TLD (tenofovir, lamivudine, and dolutegravir) ~ @FrancoisVenter3

@DTHF_SA @UCT_news @FrancoisVenter3 Islatravir is a potent antiretroviral that can be administered daily, weekly, or monthly. It is well tolerated, effective at very low doses, and has a high barrier to resistance. It also holds promise for use in combination with lenacapavir as a dual therapy regimen. However,

@DTHF_SA @UCT_news @FrancoisVenter3 Lenacapavir is a capsid inhibitor that can be administered through multiple routes. It is well tolerated, has a relatively high barrier to resistance & is approved for use in individuals with extensive treatment experience.~ @FrancoisVenter3

@DTHF_SA @UCT_news Currently, there are only three long-acting injectable formulations available–cabotegravir, rilpivirine, and lenacapavir–each developed by different pharmaceutical companies and governed by distinct global access and regulatory mandates. ~ @FrancoisVenter3

@DTHF_SA @UCT_news We need to broaden our focus to include diverse populations often overlooked in research and service delivery – such as people with tuberculosis, lactating mothers, individuals with varying body mass index (BMI), those on concurrent medications, and people who use & inject drugs.

Thank you Dr.Linda Gail Bekker for such an inspiring presentation today on the importance of the prevention push needed to protect the treatment pull #INTEREST2025